SCHEMBL246485

SCHEMBL246485

COc1cncc(-c2cnc(N3CC4(COC4)C3)cc2N)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAK O14976 1/20 0.39
BACE1 P56817 7/20 0.36
ATR Q13535 1/20 0.35
ATRIP Q8WXE1 1/20 0.35
KCNH2 Q12809 2/20 0.35
CYP11B2 P19099 4/20 0.34
CYP11B1 P15538 3/20 0.34
DYRK1A Q13627 2/20 0.34
BACE2 Q9Y5Z0 1/20 0.34
CLK1 P49759 1/20 0.34
BRD4 O60885 1/20 0.34
BRD2 P25440 1/20 0.34
BRD3 Q15059 1/20 0.34
BRDT Q58F21 1/20 0.34
ATAD2 Q6PL18 1/20 0.34
FYN P06241 1/20 0.34
GSK3B P49841 1/20 0.33
ALOX5AP P20292 1/20 0.33
CYP17A1 P05093 1/20 0.33
PIM1 P11309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL248166 0.83 ATR (0.49) GAKATRATRIPDYRK1ACLK1
SCHEMBL246486 0.80 GAK (0.41) GAK
SCHEMBL14849212 0.79 PDE10A (0.39) CYP11B2CYP11B1BRD4BRD2BRD3
SCHEMBL249136 0.78 PDE10A (0.40) CYP11B2CYP11B1BRD4BRD2BRD3
SCHEMBL29376401 0.72 CNR2 (0.37) GAKATRATRIPKCNH2CYP11B2
SCHEMBL21812349 0.72 CNR2 (0.37) GAKATRATRIPKCNH2CYP11B2
SCHEMBL248397 0.70 CYP11B1 (0.48) BACE1CYP11B2CYP11B1CYP17A1PIM1
SCHEMBL248191 0.69 ZAP70 (0.42) BACE1ATRATRIPCYP11B2CYP11B1
SCHEMBL248528 0.67 GCK (0.46) BACE1CYP11B2CYP11B1CYP17A1PIM1
SCHEMBL243086 0.66 PIK3CA (0.48) ATRATRIPDYRK1ACLK1FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588471-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY Amgen Inc. (US) 2013-05-08 EP disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 GAK 149/4885BACE1 3176/4885ATR 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.